2024
Recent trends in GLP-1 RA and SGLT2i use among people with type 2 diabetes and atherosclerotic cardiovascular disease in the USA
King A, Tan X, Dhopeshwarkar N, Bohn R, Dea K, Leonard C, de Havenon A. Recent trends in GLP-1 RA and SGLT2i use among people with type 2 diabetes and atherosclerotic cardiovascular disease in the USA. BMJ Open Diabetes Research & Care 2024, 12: e004431. PMID: 39366717, PMCID: PMC11459310, DOI: 10.1136/bmjdrc-2024-004431.Peer-Reviewed Original ResearchConceptsSodium-glucose cotransporter 2 inhibitorsGLP-1 RAsAtherosclerotic cardiovascular diseaseGLP-1Type 2 diabetesIncident useGlucagon-like peptide-1 receptor agonistsPeptide-1 receptor agonistsCardiovascular diseasePrevalence of atherosclerotic cardiovascular diseaseASCVD diagnosisProportion of patientsRetrospective observational studyNested cohort studyReceptor agonistsSGLT2i useAnalysis of cross-sectional dataSodium-glucoseCohort studyPatient numbersObservational studyPatientsPrevalent useCross-sectional dataT2D
2023
Once-weekly glucagon-like peptide-1 receptor agonists vs dipeptidyl peptidase-4 inhibitors: cardiovascular effects in people with diabetes and cardiovascular disease
Tan X, Liang Y, Rajpura J, Yedigarova L, Noone J, Xie L, Inzucchi S, de Havenon A. Once-weekly glucagon-like peptide-1 receptor agonists vs dipeptidyl peptidase-4 inhibitors: cardiovascular effects in people with diabetes and cardiovascular disease. Cardiovascular Diabetology 2023, 22: 319. PMID: 37985992, PMCID: PMC10662529, DOI: 10.1186/s12933-023-02051-8.Peer-Reviewed Original ResearchConceptsHealth care resource utilizationAtherosclerotic cardiovascular diseaseGLP-1 RAsCause health care resource utilizationPeptide-1 receptor agonistsDipeptidyl peptidase-4 inhibitorsDPP-4i usersPeptidase-4 inhibitorsMyocardial infarctionMedical costsDPP-4iIschemic strokeReceptor agonistCardiovascular diseaseGlucagon-like peptide-1 receptor agonistsWeekly glucagon-like peptide-1 receptor agonistWeekly GLP-1 RAsCause ER visitsCause hospitalization costsCause medical costsNew adult usersClinical cardiovascular outcomesObservational cohort studyType 2 diabetesCause outpatient visits
2019
Blood pressure, glycemic control, and white matter hyperintensity progression in type 2 diabetics
de Havenon A, Majersik JJ, Tirschwell DL, McNally JS, Stoddard G, Rost NS. Blood pressure, glycemic control, and white matter hyperintensity progression in type 2 diabetics. Neurology 2019, 92: e1168-e1175. PMID: 30737332, PMCID: PMC6511110, DOI: 10.1212/wnl.0000000000007093.Peer-Reviewed Original ResearchMeSH KeywordsAgedBlood GlucoseBlood PressureDiabetes Mellitus, Type 2Disease ProgressionFemaleGlycated HemoglobinHumansHypertensionLeukoaraiosisMaleMiddle AgedWhite MatterConceptsType 2 diabeticsBlood pressureWhite matter hyperintensitiesRandomization armGlycemic controlWMH progressionHigher systolic blood pressureWhite matter hyperintensity progressionIntensive blood pressureBlood pressure controlSystolic blood pressureHigh blood pressureType 2 diabetesACCORD-MINDComorbid diabetesMacrovascular complicationsCardiovascular riskHemoglobin A1cPrimary outcomeControl armMatter hyperintensitiesAggressive approachWMH volumeControl interventionsPressure control